U.S., April 11 -- ClinicalTrials.gov registry received information related to the study (NCT06922591) titled 'Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients' on March 28.
Brief Summary: TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236 or RMC-9805. The study comprises a dose escalation phase and a dose expansion phase.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
PDAC
PDAC - Pancreatic Ductal Adenocarcinoma
NSCLC
RAS Mutation
MTAP Deletion
Lung Cancer
Pancreatic Cancer Metastatic
Thoracic Cancer
Intervention:
D...